Objectives: The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of demographic and clinical features on this phenotype. Methods: Information about relapses was collected using MSBase, an international observational registry. Associations between relapse phenotypes and history of similar relapses or patient characteristics were tested with multivariable logistic regression models. Tendency of relapse phenotypes to recur sequentially was assessed with principal component analysis. Results: Among 14,969 eligible patients (89,949 patient-years), 49,279 phenotypically characterised relapses were recorded. Visual and brainstem relapses occurred more frequently in early disease and in younger patients. Sensory relapses were more frequent in early or non-progressive disease. Pyramidal, sphincter and cerebellar relapses were more common in older patients and in progressive disease. Women presented more often with sensory or visual symptoms. Men were more prone to pyramidal, brainstem and cerebellar relapses. Importantly, relapse phenotype was predicted by the phenotypes of previous relapses. (OR = 1.8-5, p = 10 -14 ). Sensory, visual and brainstem relapses showed better recovery than other relapse phenotypes. Relapse severity increased and the ability to recover decreased with age or more advanced disease. Conclusion: Relapse phenotype was associated with demographic and clinical characteristics, with phenotypic recurrence significantly more common than expected by chance.
Introduction
Clinical relapses in multiple sclerosis (MS) can result in residual functional impairment, 1, 2 and may lead to long-term accumulation of disability. [3] [4] [5] They have a significant impact on patients' quality of life and employability and contribute to healthcare-related expenses. Therefore, reduction of relapse frequency is a common primary outcome in clinical trials of immunomodulatory agents.
In some demyelinating diseases, such as neuromyelitis optica, relapses occur almost exclusively in specific neuroanatomical regions. However, in MS, our knowledge of relapse phenotype recurrence is limited. It is the experience of many clinicians that patients presenting with certain symptoms or signs experience further relapses with a similar phenotype. This clinical impression was substantiated in a single-centre study of 195 patients, showing an increased recurrence risk of Multiple Sclerosis Journal 20 (11) phenotypically similar first and second relapses after a first attack. 6 More specifically, this association was apparent for relapses affecting the spinal cord, optic nerve, brainstem and cerebellum.
In this study, we used the international MSBase registry dataset to assess the risk of phenotypic relapse recurrence in a large, representative MS population, 7 with long-term, prospectively acquired follow-up data. We examined recurrence relationships between various relapse phenotypes and characterised relapse patterns in relation to clinical and demographic data.
Patients and methods
Data collection in the MSBase registry was approved by the Melbourne Health Human Research Ethics Committee, 7 and by the local ethics committees in all participating centres (or exemptions granted, according to applicable local laws and regulations). Written informed consent was obtained from enrolled patients as required.
Longitudinal clinical data from 18,885 patients from 55 MS centres in 25 countries were extracted from the MSBase registry in February 2012. Inclusion criteria consisted of a diagnosis of MS or clinically isolated syndrome (CIS) and availability of minimal dataset. The minimal dataset consisted of patient date of birth, sex, MS centre, dates of MS onset and clinical followup, disease course at inclusion and censoring, dates of disease modifying therapy and list of clinical relapses (including date of onset, clinical presentation and treatment status). Expanded Disability Status Scale (EDSS) score at inclusion and censoring was not required. Patients with primary progressive MS were excluded.
The analysed data were recorded as part of routine clinical practice, with real time or near-real time data entry in relation to clinical visits. Relapse information was recorded when reported by patients, however, retrospective entry of pre-MSBase relapses was allowed. The MSBase protocol stipulates minimum annual updates of the minimum dataset, but patients with less frequent visits were not excluded. Data entry portal was either the iMed clinical record system or the MSBase online data entry system. Data quality assurance procedures are described elsewhere. 8 MS course was classified by treating neurologists as CIS, relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) or relapsing-progressive MS (RPMS). Progressive MS was defined by continuous clinical progression over at least one year. Onset of progressive phase was identified by participating neurologists. Disability was assessed by accredited scorers using EDSS (neurostatus certification was required at each centre). A clinical relapse was defined as occurrence of new symptoms or exacerbation of existing symptoms persisting for at least 24 hours, in the absence of concurrent illness or fever, and occurring at least 30 days after a previous relapse. 9 For the purpose of this study, the initial attack was referred to as a relapse. For all analysed relapses, new or worsening signs/symptoms were classified according to functional domains defined by Kurtzke. 10 Formal scoring of relapse-associated disability was not required. A proportion of relapses were classified by the clinicians as mild, moderate or severe, as described elsewhere, 11 and the presence/absence of their impact on activities of daily living was reported by patients. In a subset of relapses, clinical recovery was evaluated by the neurologists as complete or incomplete. Treatment of relapses with glucocorticoids was recorded.
Statistical analysis was carried out using Statistica 10 (Statsoft, Tulsa, USA) and R (http://www.R-project. org). All hypotheses were tested at a two-tailed 0.05 level of significance, after applying Benjamini-Hochberg correction for multiple hypothesis testing. To evaluate independent determinants of relapse phenotype, a multivariable logistic regression model was built for each functional system, with the relapse phenotype (dichotomised as present/absent) as the dependent variable and sex, age, MS duration, MS course and presence/absence of phenotypically similar previous relapses as independent predictors. A separate series of multivariable logistic regression models were used to evaluate independent determinants of relapse severity (mild/moderate/severe), impact on activities of daily living (present/absent) and recovery (complete/incomplete), with the tested candidate determinants being sex, age, MS duration, MS course and relapse phenotype. The effect of total number of previous relapses was evaluated in a separate multivariable logistic model. In the subpopulation of patients followed in MSBase from CIS and at least one relapse following the initial episode, a multivariable logistic model was built to evaluate the initial relapse phenotype as a determinant of the subsequent dominant (i.e. the most frequent) relapse phenotype. Multiple dominant phenotypes were allowed where several phenotypes were tied. The dependent variable (dichotomised) indicated convergence between the phenotypes of the initial and the subsequent relapses, with independent predictors comprising relapse phenotype, sex, age, centre and date of relapse onset. All models were adjusted for MS-specific therapy, centre and date of relapse onset, and the analysis of recovery was adjusted for steroid therapy (present/absent). Goodness of model fit was evaluated with the Akaike information criterion. 
Results

Patients and relapses
Of the 18,885 patients with data in the MSBase registry in February 2012, data from 14,969 patients and 89,949 patient-years were retained ( Figure 1 ). The number of eligible patients per centre varied between 20 and 1340. Population characteristics are shown in Table 1 and Supplementary Figure 1 (online). Relapse phenotypes by country are shown in Supplementary Table 1 (online). Overall, 49,279 relapses with recorded presenting symptoms were analysed (3.8±3.2 (mean±standard deviation) per patient; Table 2 ). The majority of relapses were monosymptomatic (71.4%) and presented with sensory, pyramidal or visual symptoms/signs. Figure 2 shows relapse phenotypes stratified by demographic and clinical features. Table 3 summarises outcomes of the respective multivariable logistic models. Pyramidal, cerebellar or brainstem relapses occurred more commonly in men (odds ratio (OR) = 1.1, p ≤ 0.03), visual or sensory relapses were more frequent in women (OR = 1.13, p ≤ 0.02). Older age was positively associated with pyramidal and bowel/bladder relapses (OR = 1.02, p ≤ 10 -8 ), and negatively associated with visual and brainstem relapses (OR = 0.98-0.99, p ≤ 0.008). Longer MS duration was positively associated with cerebellar relapses (OR = 1.02, p = 0.046) and negatively associated with visual, sensory and brainstem relapses (OR = 0.94-0.99, p ≤ 0.023). Compared to the relapses recorded in RRMS, CIS more commonly affected the visual system (OR = 2.04, p = 0.048). SPMS was positively associated with bowel/bladder relapses (OR = 2.46, p = 10 -5 ), and negatively associated with brainstem and cerebellar relapses (OR = 0.26-0.28, p ≤ 0.05). The relatively rare RPMS was negatively associated with visual, sensory and brainstem relapses (OR = 0.39-0.63, p < 10 -6 ), and positively associated with pyramidal, bowel/bladder, cerebellar and cognitive relapses (OR = 2.05-2.82, p<10 -4 ). Disease modifying therapy at the time of relapse did not have a significant impact on relapse phenotype.
Relapse phenotypes
Relapse recurrence
Relapses were significantly more likely to present with the same phenotype as the preceding relapses (OR = 1.8-5, p = 10 -14 ; Table 3 ), regardless of the number of previous relapses. In patients with data recorded from CIS and ≥2 documented relapses (7612, 72% women, age 30±10 years), we examined associations between the initial relapse and the most frequent subsequent relapse phenotype. We observed a significantly increased likelihood of the subsequent relapses to affect the same neurological function as the initial relapse for visual, pyramidal, sensory, cerebellar and brainstem relapses ( Table 4 ). This association was most pronounced for sensory (OR = 7.71) and pyramidal relapses (OR = 4.99, p = 10 -15 ).
We also conducted a principal component analysis to identify patterns of relapse phenotypes which were likely to occur in conjunction or consecutively in individual patients over the course of MS. The analysis identified a single component explaining 31% of variance in relapse phenotypes (eigenvalue 2.15). This component consisted of pyramidal (loading 0.68) and bowel/bladder (0.65) relapses, followed by sensory (0.59), cerebellar (0.56) and brainstem (0.54) relapses, and finally cognitive (0.41) and visual (0.39) relapses ( Supplementary Figure 2 online), suggesting that the closest associations exist between pyramidal, bowel/ bladder and sensory phenotypes.
Relapse severity, impact and recovery
Information about clinical severity was available for 17,282 relapses (35%). The availability of information about severity was proportional across the phenotypes (34-45%), with the exception of cognitive relapses, where it reached 59%. With the exception Multiple Sclerosis Journal 20 (11) of sensory relapses, all relapses were more likely to be classified as moderate or severe rather than mild (OR = 1.15-2.98, p ≤ 0.042; Table 5 ). In addition, moderate relapse severity was positively associated with patient age (OR = 1.01, p = 0.013) and negatively associated with female sex (OR = 0.95, p = 0.042). Both moderate and severe relapses were less frequent in CIS compared to RRMS (OR = 0.44-0.71, p ≤ 0.003).
With the exception of sensory relapses (OR = 0.91, p = 0.017), all relapse phenotypes were likely to impact on activities of daily living (OR = 1.29-2.97, p ≤ 0.012), with the impact of pyramidal and cerebellar relapses being the most prominent. The relapses with significant impact on daily activities were more common among patients with longer disease duration (OR = 1.01, p = 0.049) and were less common in CIS (OR = 0.59, p = 0.0001). Pyramidal, bowel/bladder, cognitive and cerebellar relapses had increased risk of incomplete recovery resulting in residual disability (OR = 1.34-1.40, p ≤ 10 -6 ; adjusted for corticosteroid treatment). In contrast, brainstem relapses were more likely to recover without clinical residuum (OR = 0.91, p = 10 -5 ). Incomplete recovery was more common in SPMS (OR = 1.52, p = 0.0007) and RPMS (OR = 2.24, p = 10 -10 ) compared to RRMS and less common in CIS (OR = 0.58, p = 10 -8 ) and in females (OR = 0.96, p = 0.012). The likelihood of incomplete recovery increased independently with age (OR = 1.03, p < 10 -15 ) and number of previous relapses (OR = 1.04, p = 10 -8 ) but not with disease duration (p = 0.4).
Discussion
Using data from approximately 15,000 patients representing almost 90,000 patient-years recorded in the observational international MSBase registry and representative of MS population managed in academic MS centres, we have examined trends in clinical presentations of MS relapses.
We have shown that relapses tend to recur within previously affected neurological domains. Sensory, pyramidal, visual, brainstem or cerebellar initial relapses are predictive of the predominant phenotype of future relapses. Our observations confirm and extend prior published work. In a cohort of 195 patients, Mowry et al. showed that initial events in CIS localised to the spinal cord, optic nerve or brainstem/ cerebellum were commonly followed by relapses of similar phenotype. 6 In addition, relapses in patients on first-line immunomodulatory therapy were often preceded by similar pre-treatment relapses. 12 Our principal component analysis suggested that the relapse phenotypes occurring consecutively in individual patients are most likely to affect anatomically related functions. The most significant associations were found between pyramidal, bowel/bladder and sensory relapses. This is strongly suggestive of their co-localisation in the spinal cord. It could be hypothesised that anatomical distribution of inflammatory activity is an inherent property of individual MS phenotype with a great inter-individual variability. This view is supported by several studies demonstrating associations between lesion distribution and genetic or Multiple Sclerosis Journal 20 (11) immunological variables. [13] [14] [15] Cumulative structural damage resulting from previous relapses might diminish local functional reserve and thus enhance the impact of any further inflammatory activity on the previously affected neurological networks. Autopsy studies have shown that demyelination commonly occurs in previously remyelinated areas and may represent a pathological correlate of disability progression. 16, 17 In support of this concept, accrual of persistent disability within the visual, pyramidal, sensory or cerebellar systems is commonly preceded by clinical relapses within corresponding anatomical locations. 18 Multiple Sclerosis Journal 20 (11) The phenotype of CIS has previously been characterised. 19 However, a complex evaluation of clinical events and their presentations, severity, impact and recovery, with detailed analysis capturing the full spectrum of MS courses, duration and patient demography has not been performed. In this study we have shown that relapse patterns vary according to age, sex, MS course and MS duration. Compared to the relapses in clinically definite MS, initial events are more likely to involve visual function. In a population-based sample of 1424 patients, Cossburn et al. reported the following proportions of the initial events: visual 18%, long tract 47%, cerebellar 10%, brainstem 10%, cerebral 1% and polyregional 11%. 19 Our observations generally confirm these results (see Table 4 ). However, a direct comparison between the two studies is not possible due to differing clinical classification of relapses. The likelihood of visual relapses decreases with longer MS duration, older patient age and more progressive MS course. This is also in agreement with the previously cited work, which showed that optic neuritis as an initial event is most common among children and decreases with age. 19 A similar pattern is apparent for the relapses affecting brainstem functions. Additionally, the likelihood of sensory relapses decreases with MS duration and is also lower in RPMS. In contrast, the risk of pyramidal and bowel/bladder relapses increases with more progressive disease course and older age. Here again our observations are in agreement with those of Cossburn et al., 19 who reported age-dependent increase in the incidence of CIS affecting sphincter, sexual and locomotor functions. The likelihood of cerebellar relapses increases with MS duration and is higher in RPMS. It should be noted that the higher proportion of cerebellar relapses in SPMS compared to RRMS seen in unadjusted data is most likely driven by other confounders (such as sex, age and MS duration) as the statistical models showed a negative independent association.
In our cohort, sensory and bowel/bladder relapses were disproportionately low and pyramidal, cerebellar and brainstem relapses were high among children younger than 10 years. With the exception of cognitive relapses, our results are similar to those reporting 245 relapses from 105 MS patients younger than 18 years: visual 24-26%, spinal cord 36-41%, brainstem/cerebellar 39-51% and cerebral 9-11%. 20 This phenomenon could be attributed to underreporting of sensory and sphincter presentations in paediatric patients.
We have shown that relapses are more likely to present with sensory or visual symptoms in women, and with pyramidal, brainstem or cerebellar symptoms in men. It is of interest that sensory relapses are less likely to interfere with activities of daily living and both sensory and visual relapses are less likely to result in incomplete recovery. Therefore we may expect that women should present with milder relapses with a better prospect of recovery compared to men, an assumption which has been confirmed by our data. We and others previously demonstrated that relapses are more frequent among women than in men, 21, 22 and that higher relapse frequency early in the disease course is associated with less favourable disability outcomes. 4, 24, 25 In contrast, several other Multivariable logistic model with the outcome variable describing phenotypic similarity between the initial relapse and the subsequent relapses, and independent variables comprising relapse phenotype, sex, age, centre and date of relapse onset. The analysed patients were followed in MSBase from clinically isolated syndrome and had at least one documented relapse following the initial event (n = 7612). a Defined as patients in whom the initial events and the predominant clinical presentations of the subsequent relapses affected the same functional neurological domains. CI = confidence interval; OR = odds ratio.
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studies suggested that male sex predisposes to poorer long-term disease outcomes. 25, 26 This seemingly conflicting evidence could potentially be explained by the impact of relapse severity and recovery on disability outcomes. It has been shown that more severe relapses are less likely to recover completely, 27 and that a poor recovery from relapses leads to more pronounced disability accrual. 2, 25, 28, 29 Therefore, we can speculate that women, who are more likely to experience more frequent but less severe relapses with better recovery, will also show better long-term disease outcomes than men.
We have observed that relapses with higher impact and poorer recovery were associated with longer MS duration, progressive disease course or older age. With the exception of age, these observations are in agreement with previously published data. 19, 30 . In addition, sensory relapses are of relatively lower severity and impact, and together with visual and brainstem relapses are relatively less likely to result in incomplete recovery compared to the other relapse phenotypes.
A potential limitation of our study is the quality of the data collected within MSBase, which is likely to be lower in an observational registry than in a clinical trial. Recall bias could play a role in an observational database, where the relapse information is usually recorded retrospectively at the clinical visit following the onset of the relapse. In addition, under-reporting of relapses could conceivably confound results but would have to occur differentially to do so. Reassuringly, our previous work studying incidence of relapses in MSBase, which used a cohort largely overlapping with the cohort used in our present analysis, 21 showed annual relapse rates which were similar to the relapse rates in the recent randomised controlled trials (0.3-0.4 within the initial 10 years from disease onset). 31, 32 Given the reporting of relapses may change over time, we adjusted all analyses for relapse date. Further variance could potentially be introduced by the differences in clinical classification of relapses between evaluating physicians. In relation to disability severity and phenotype, patients may be biased in reporting certain relapse phenotypes. In a large proportion of relapses the information about severity, impact and recovery was not recorded, and where available, this information was based on subjective assessment. Preferential recording of this information in relapses with specific presentation or severity, or in specific disease course could have potentially confounded the analysis. Finally, the studied population was representative of patient populations managed at large academic MS centres, which may impact on the generalisation of our observations.
In conclusion, the demonstrated propensity of relapses to involve previously affected functions could reflect increased vulnerability of previously demyelinated CNS regions to further autoimmune attacks. 16, 17, 33 The increased likelihood of men to suffer pyramidal relapses, especially as these are also likely to be recurrent, may at least partially explain the widely reported worse disability progression outcomes in men. We plan to examine this relationship in future work. Multiple Sclerosis Journal 20 (11) In spite of increased risk of phenotypic recurrence in individual patients' relapses, there is also a completely unexplained decrease in the proportion of visual relapses and a concomitant increase in the proportion of pyramidal and sphincter relapses with older age, longer disease duration and in progressive MS. Discovery of a neurobiological substrate for this shift could have major implications for our understanding of MS pathogenesis. 
